| Family Eye Care Associates-kapolei, Llc. | |
|
1001 Kamokila Blvd # 108, James Campbell Bldg., Kapolei, HI 96707-2014 | |
| (808) 674-0085 | |
| (808) 674-8785 |
| Full Name | Family Eye Care Associates-kapolei, Llc. |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 1001 Kamokila Blvd # 108, Kapolei, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700011996 | NPI | - | NPPES |
| 0000238154 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 572 (Hawaii) | Primary |
| Provider Name | Todd Nakagawa |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1679598619 PECOS PAC ID: 6103962279 Enrollment ID: I20091006000248 |
News Archive
Vacationing at the shore led to a 5 percent increase in nevi (more commonly called "moles") among 7-year-old children, according to a paper published in Cancer Epidemiology, Biomarkers and Prevention , a journal of the American Association for Cancer Research.
A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).
A team of researchers from the US and UK used the AGM intranasal model of SARS-CoV-2 infection to determine differences between a contemporary SARS-CoV-2 D614G variant circulating in summer 2020 and the B.1.1.7 UK variant of concern that emerged in late 2020.
W. L. Gore & Associates (Gore) today provided an update on the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study, which includes up to fifty investigational sites in the U.S., Denmark, Finland, Norway and Sweden, is on track to meet its estimated completion in 2015.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Family Eye Care Associates-kapolei, Llc. 1001 Kamokila Blvd # 108, James Campbell Bldg., Kapolei, HI 96707-2014 Ph: (808) 674-0085 | Family Eye Care Associates-kapolei, Llc. 1001 Kamokila Blvd # 108, James Campbell Bldg., Kapolei, HI 96707-2014 Ph: (808) 674-0085 |
News Archive
Vacationing at the shore led to a 5 percent increase in nevi (more commonly called "moles") among 7-year-old children, according to a paper published in Cancer Epidemiology, Biomarkers and Prevention , a journal of the American Association for Cancer Research.
A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).
A team of researchers from the US and UK used the AGM intranasal model of SARS-CoV-2 infection to determine differences between a contemporary SARS-CoV-2 D614G variant circulating in summer 2020 and the B.1.1.7 UK variant of concern that emerged in late 2020.
W. L. Gore & Associates (Gore) today provided an update on the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study, which includes up to fifty investigational sites in the U.S., Denmark, Finland, Norway and Sweden, is on track to meet its estimated completion in 2015.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.
› Verified 3 days ago
Dr. Christopher Sween Optometrist Inc Optometrist Medicare: Medicare Enrolled Practice Location: 4589 Kapolei Pkwy, Kapolei, HI 96707 Phone: 808-674-3913 Fax: 808-674-3914 | |
Eyes Plus Inc Optometrist Medicare: Medicare Enrolled Practice Location: 590 Farrington Hwy, 220, Kapolei, HI 96707 Phone: 808-674-0744 Fax: 808-674-0977 | |
Precision Vision Optometrist Medicare: Not Enrolled in Medicare Practice Location: 579 Farrington Hwy, Suite 101, Kapolei, HI 96707 Phone: 808-674-8811 | |
Mr. Henry Lyman Makini, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 590 Farrington Hwy Unit 220, Kapolei, HI 96707 Phone: 808-674-0744 | |
Dr. Lea U Young, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 511 Manawai St Apt 401, Kapolei, HI 96707 Phone: 808-674-2273 | |
Dr. Wendi Nobuko Harada Shibayama, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 91-600 Farrington Hwy Unit 3, Kapolei, HI 96707 Phone: 808-674-4488 | |
Dr. William A Whalley, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 579 Farrington Hwy, #101, Kapolei, HI 96707 Phone: 808-674-8811 Fax: 808-674-8899 |